FDA approves marketing of two cognitive skill tests for head trauma

After a traumatic head injury, most cognitive skills tests are done by physicians at the hospital well after the initial impact. The FDA announced it will allow the marketing of two devices capable of assessing a patient's cognitive function immediately after a suspected brain injury or concussion.

The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and ImPACT Pediatric are the both medical software systems to assess cognitive function combine information from a physician on the symptoms of a head injury. ImPACT runs on a laptop or desktop computer for patients ages 12 to 59, while the ImPACT Pediatric runs on an iPad for children ages 5 to 11.

While not intended to diagnose concussions or determine treatments, these tools are intended to test cognitive skills such word memory, reaction time and word recognition, which are all affected by head injury.  The results of the test are then compared to age-match data in a database of the patient’s pre-injury baseline scores.

"These devices provide a useful new tool to aid in the evaluation of patients experiencing possible signs of a concussion, but clinicians should not rely on these tests alone to rule out a concussion or determine whether an injured player should return to a game," said Carlos Peña, PhD, MS, director of the division of neurological and physical medicine devices at the FDA's Center for Devices and Radiological Health.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.